Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.
Visser
W Hester
WH
Merck Research Laboratories, West Point, PA 19486, USA.
Winner
Paul
P
Strohmaier
Kim
K
Klipfel
Meghan
M
Peng
Yahong
Y
McCarroll
Kathleen
K
Cady
Roger
R
Lewis
Donald
D
Nett
Robert
R
D000208:Acute Disease; D000293:Adolescent; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D012008:Recurrence; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014363:Tryptamines
D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan